
CROI to Present New Insights on Long COVID Risk, HIV Cure
One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential causes, biomarkers, and the significance of viral rebound.
A virologist and physician-scientist at Johns Hopkins Medicine, Annie Antar, MD, PhD, will be presenting research on long COVID and viral rebound and clearance at the
In this interview, she previews findings she will be presenting from
Primary findings of this research are that slower viral clearance was strongly associated with development of long COVID, having more symptoms equated with slower viral clearance, and a potential link was found between viral rebound and higher risk of developing long COVID.
“For the people who did report having long COVID, having a higher slope—so that means a slower viral clearance rate—was strongly associated with having long COVID later,” she explains. “And it actually had kind of a dose-response curve, where the people who had more symptoms had the slower clearance.”
In addition to her own research, Antar says she is looking forward to Monday’s plenary personation on HIV cure from Ole S. Søgaard, PhD, professor, Department of Clinical Medicine/Infectious Diseases, Aarhus University; conference sessions on long COVID, including the Wednesday plenary presentation on long COVID from Roger Paredes, MD, PhD, head of the Infectious Diseases Department at the Hospital Germans Trias i Pujol; and sessions on viral rebound, HIV, and neuropathogenesis and proviral landscapes.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.